The effect of Bozungikgitang on the fatigue, and general weakness in the postoperative thyroid cancer patients receiving thyroid hormone replacement therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001414

Enrollment

Registered

2015-03-16

Start date

2015-03-05

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : There is no special treatment control group, the test group bojung ikgitang / oral / twice a day (once 1 package (4.5g) each, morning and evening meal 30 minutes) and at 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? subject to target patients underwent total thyroidectomy. ? surgery despite taking of thyroid hormones received thyroid papillary carcinoma, and fatigue in patients complained least three months. ? And at the age of between19 ~80 years of age in patients .

Exclusion criteria

Exclusion criteria: ? if the patient does not agree with this study is excluded from the study. ? The age of patients less than 19 years old, 80 years of age or older, with the exception of the case. ? systemic symptoms if administered by a non-defective bojung ikgitang are excluded. ? person participating in another clinical studies excluded. ? pregnant women, nursing mothers, women of childbearing age are excluded unless adequate contraception. ? thyroid function test abnormal hormone levels, factors are excluded. (Free T4 is abnormal while excluding subjects of TSH 5 )

Design outcomes

Primary

Measure	Time frame
fatigue scale	—

Secondary

Measure	Time frame
8-hydroxy-2’-deoxyguanosine (8-OHdG), EORTC-QoL questaionnaire	—

Countries

Korea, Republic of

Contacts

Public Contacteunyoung Ko

Daegu Catholic Univercity Medical Center

keylgh0905@naver.com+82-53-650-4098

Outcome results